Analytics - Page 3 of 17

A new Nature Communications study suggests that insulin resistance tracks with higher risk for 12 cancer types. An international research team applied an unusual approach — instead of measuring insulin resistance directly, they developed an algorithmic proxy, opening the door to population-scale risk analyses. Here’s why that matters.

In recent years, GLP-1–based weight-loss drugs have decisively moved beyond a narrow medical topic and become a mainstream subject of discussion in the US, Europe, and Canada. Explosive demand growth, intensifying competition, and expectations of change driven by patent timelines have turned the search for Ozempic alternatives into a practical question: what should you choose if Ozempic is hard to obtain, too expensive, or poorly tolerated?

The word “rejuvenation” covers everything from cosmetics and supplements to lab work that tries to change how cells age — and, in turn, how age-related disease risk builds up. This article is a short guide to the science-backed version of that conversation: what geroscience is, what the Hallmarks of Aging are, and why investors are pouring billions into the space.